JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

Начало・Списък с акции・Novocure Ltd

Novocure Ltd

Затворен

СекторЗдравеопазване

12.15 -1.78

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

12.05

Максимум

12.54

Ключови измерители
By Trading Economics
Приходи	2.9M -37M
Продажби	8.4M 167M
EPS	-0.33
Марж на печалбата	-22.29
Служители	1,488
EBITDA	9.7M -26M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+90.16% upside

Дивиденти
By Dow Jones
Следващи печалби	26.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-33M 1.5B
Предишно отваряне	13.93
Предишно затваряне	12.15

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

16.31 / 18.14 Подкрепа & съпротива

Novocure Ltd Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.02.2026 г., 23:52 ч. UTC

Придобивния, сливания и поглъщания

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2.02.2026 г., 23:52 ч. UTC

Придобивния, сливания и поглъщания

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2.02.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2.02.2026 г., 23:38 ч. UTC

Пазарно говорене

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2.02.2026 г., 23:28 ч. UTC

Пазарно говорене

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2.02.2026 г., 23:23 ч. UTC

Печалби

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2.02.2026 г., 22:57 ч. UTC

Печалби

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2.02.2026 г., 22:22 ч. UTC

Придобивния, сливания и поглъщания

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2.02.2026 г., 22:08 ч. UTC

Пазарно говорене

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2.02.2026 г., 21:51 ч. UTC

Печалби

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

2.02.2026 г., 21:49 ч. UTC

Печалби

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2.02.2026 г., 21:39 ч. UTC

Печалби

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2.02.2026 г., 21:36 ч. UTC

Печалби

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2.02.2026 г., 21:34 ч. UTC

Печалби

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2.02.2026 г., 21:28 ч. UTC

Придобивния, сливания и поглъщания

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2.02.2026 г., 21:23 ч. UTC

Печалби

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2.02.2026 г., 21:19 ч. UTC

Печалби

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2.02.2026 г., 21:17 ч. UTC

Печалби

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2.02.2026 г., 21:17 ч. UTC

Печалби

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2.02.2026 г., 21:10 ч. UTC

Печалби

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2.02.2026 г., 21:08 ч. UTC

Печалби

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2.02.2026 г., 21:07 ч. UTC

Печалби

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2.02.2026 г., 21:05 ч. UTC

Печалби

Palantir Technologies 4Q Net $608.7M >PLTR

2.02.2026 г., 21:05 ч. UTC

Печалби

Palantir Technologies 4Q Rev $1.41B >PLTR

2.02.2026 г., 21:05 ч. UTC

Печалби

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2.02.2026 г., 21:05 ч. UTC

Печалби

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2.02.2026 г., 21:05 ч. UTC

Печалби

Palantir Technologies 4Q Adj EPS 25c >PLTR

2.02.2026 г., 21:05 ч. UTC

Печалби

Palantir Technologies 4Q EPS 24c >PLTR

2.02.2026 г., 20:40 ч. UTC

Пазарно говорене

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Novocure Ltd Прогноза

Ценова цел

By TipRanks

90.16% нагоре

12-месечна прогноза

Среден 23.58 USD 90.16%

Висок 39 USD

Нисък 13.5 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Novocure Ltd през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Novocure Ltd през последните 3 месеца.

Техническа оценка

By Trading Central

16.31 / 18.14Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Novocure Ltd

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.